Advanced Oncotherapy

 

  • Home
  • Our Research Interests
    • Understanding our Scientific Commitment
    • The Potential of Proton Therapy
    • More Applications and Research Interests
  • Our Technology
    • Overview of the LIGHT System
    • The LIGHT System Module by Module
    • Toward the First Installation of LIGHT
  • Our Company
    • About Us
    • Our History
    • Media Room
  • Investor Relations
    • AIM Rule 26 Information
    • Company Documents
    • Corporate Governance
    • Regulatory News
    • Share Price Information
    • Shareholder Analysis
    • Advisers & Registrar
  • Careers
  • Contact Us
  • Home
  • Our Research Interests
    • Understanding our Scientific Commitment
    • The Potential of Proton Therapy
    • More Applications and Research Interests
  • Our Technology
    • Overview of the LIGHT System
    • The LIGHT System Module by Module
    • Toward the First Installation of LIGHT
  • Our Company
    • About Us
    • Our History
    • Media Room
  • Investor Relations
    • AIM Rule 26 Information
    • Company Documents
    • Corporate Governance
    • Regulatory News
    • Share Price Information
    • Shareholder Analysis
    • Advisers & Registrar
  • Careers
  • Contact Us

You are here:   Investor Relations * Regulatory News

Regulatory News Announcements

Investor Relations
  • AIM Rule 26 Information
  • Company Documents
  • Corporate Governance
  • Regulatory News
  • Share Price Information
  • Shareholder Analysis
  • Advisers & Registrar
Research Interests
  • ADAM, a Research company inspired by CERN
  • The Potential of Proton Therapy
  • More Applications and Research Interests
Technology
  • Overview of the LIGHT System
  • The LIGHT System Module by Module
  • Toward the First Installation of LIGHT
Company
  • About Us
  • Our History
  • Media Room
Investor Relations
  • AIM Rule 26
  • Company Documents
  • Share Price Information
Copyright 2018 by Advanced Oncotherapy

Site by Purple Creative Studio - Login

The presentation of the AVO's LIGHT Proton Therapy Solution is part of our Development roadmap and is subject to conformity assessment(s) by AVO's Notified Body as well as 510(k) clearance by the USA-FDA
Terms of Use Privacy Statement